BRIEF-Plus Therapeutics Announces FDA Agreement To Initiate ReSPECT-LM Dose Optimization Trial For REYOBIQ In Leptomeningeal Metastases

Reuters
30 Jun
BRIEF-Plus <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces FDA Agreement To Initiate ReSPECT-LM Dose Optimization Trial For REYOBIQ In Leptomeningeal Metastases

June 30 (Reuters) - Plus Therapeutics Inc PSTV.O:

  • PLUS THERAPEUTICS ANNOUNCES FDA AGREEMENT TO INITIATE RESPECT-LM DOSE OPTIMIZATION TRIAL FOR REYOBIQ™ IN LEPTOMENINGEAL METASTASES

  • PLUS THERAPEUTICS INC - TRIAL TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY ENDPOINTS

  • PLUS THERAPEUTICS INC - TRIAL TO ENROLL UP TO 24 PATIENTS AT 44.1 MCI DOSE

Source text: ID:nGNX2L2Dlq

Further company coverage: PSTV.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10